BONE MINERAL DENSITY IN PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY

Published: 19-12-2012
Last updated: 26-04-2024

To assess whether a change in BMD as detected big DXA (gold standard) is comparable with the decline measured by the achilles method

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Bone, calcium, magnesium and phosphorus metabolism disorders
Study type	Observational invasive

Summary

ID

NL-OMON37103

Source
ToetsingOnline

Brief title
BMD during ADT

Condition

- Bone, calcium, magnesium and phosphorus metabolism disorders
- Renal and urinary tract neoplasms malignant and unspecified

Synonym
bone loss, osteoporosis

Research involving
Human

Sponsors and support

Primary sponsor: Sint Franciscus Gasthuis
Source(s) of monetary or material Support: Abbott,grant van farmaceutische industrie

Intervention

Keyword: Achilles, androgen deprivation, Bone mineral density, prostate cancer

Outcome measures

Primary outcome

Compare the change in BMD between the 2 modalities

Secondary outcome

describe course of BMD of both modalities

Identify factors that influence the BMD pattern

Study description

Background summary

ADT can cause osteoporosis. Recognition of patients in whom a decline in BMD will occur is difficult

Study objective

To assess whether a change in BMD as detected big DXA (gold standard) is comparable with the decline measured by the achilles method

Study design

serial BMD measurements by achilles and DXA-scan

Study burden and risks

see above

Contacts

Public
Sint Franciscus Gasthuis

Kleiweg 500
3045PM
NL
Scientific
Sint Franciscus Gasthuis

Kleiweg 500
3045PM
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Prostate cancer
androgen deprivation according to Bolla schedule

Exclusion criteria

osteoporosis
treatment with bisphophonates or RANK-ligand inhibitor

Study design

Design

Study type: Observational invasive

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Diagnostic

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	26-06-2013
Enrollment:	51
Type:	Actual

Ethics review

Approved WMO

Date:	19-12-2012
Application type:	First submission
Review commission:	TWOR: Toetsingscommissie Wetenschappelijk Onderzoek Rotterdam e.o. (Rotterdam)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL40673.101.12